Debbie Rigby rounds up the latest in research news
In this study of 50 people with gout and serum uric acid (SUA) >0.35mmol/L, tart cherry concentrate had no effect on SUA or urine urate excretion. Allopurinol use did not modify the effect of cherry on SUA or urine urate excretion. It is thought that cherries may prevent gout flares because cherry concentrate contains anthocyanin, a naturally occurring anti-inflammatory molecule that inhibits cyclooxygenase activity and scavenges reactive nitric oxide radicals.
Insights from the SWEDEHEART Registry show ticagrelor use among older patients after a myocardial infarction was associated with higher risk of bleeding and death compared with clopidogrel. In patients aged 80 years and older, ticagrelor was associated with a 17% and 48% higher risk of death compared to clopidogrel. Among patients younger than 80 years, ticagrelor was associated with 15% lower risk of death, 32% higher risk of bleeding, but a lower risk of MI and stroke.
The Australian COPS Randomized Clinical Trial demonstrated that the addition of colchicine to standard medical therapy did not significantly affect cardiovascular outcomes at 12 months in ACS patients and was associated with a higher rate of mortality. Patients were assigned to receive either colchicine (0.5mg twice daily for first month, then 0.5mg daily for eleven months) or placebo, in addition to standard secondary prevention pharmacotherapy.
The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). Patients benefit from early (within 3 days), in-hospital initiation of colchicine (0.5mg once daily) after an MI. The beneficial effects of early initiation of colchicine were also demonstrated for urgent hospitalization for angina requiring revascularization (HR = 0.35), all coronary revascularization (HR = 0.63), and the composite of cardiovascular death, resuscitated cardiac arrest, MI, or stroke (HR = 0.55).
European Heart Journal, ehaa659.